Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pandemic Perspectives: Safety Monitoring Boost For COVID Vaccines Creating ‘A New Normal’ For Pharmacovigilance

Executive Summary

Pink Sheet infographic puts together the many new and existing safety systems being used to track and evaluate COVID-19 vaccine adverse events. There are early signs the vaccination effort has led to heightened public attention on medication safety that may be here to stay.

You may also be interested in...

FDA Advisors Give Entasis Antibiotic Unanimous Thumbs Up, But Call For Strong Postmarket Surveillance

High unmet need and a potentially more favorable safety profile than current options got sulbactam-durlobactam a favorable advisory panel.

Califf: FDA Vaccine Safety Oversight Would Be Enhanced By Federal Public Health Data Authority

US FDA continues to push for new federal funding and authorities to improve vaccine safety surveillance.

PDUFA VII Will Fund Pregnancy Postmarket Safety Update, Sentinel Upgrades, REMS Standardization

US FDA will incorporate performance goals for reviewing REMS methodological approaches and study protocols as part of PDUFA reauthorization.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts